相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。α-Smooth muscle actin is an inconsistent marker of fibroblasts responsible for force-dependent TGFβ activation or collagen production across multiple models of organ fibrosis
Kai-Hui Sun et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2016)
Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition
Daisuke Katagiri et al.
KIDNEY INTERNATIONAL (2016)
TGF-β: the master regulator of fibrosis
Xiao-ming Meng et al.
NATURE REVIEWS NEPHROLOGY (2016)
Poly (ADP-Ribose) Polymerase-1 Is a Key Mediator of Liver Inflammation and Fibrosis
Partha Mukhopadhyay et al.
HEPATOLOGY (2014)
Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity
Jinu Kim et al.
KIDNEY INTERNATIONAL (2012)
Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury
Partha Mukhopadhyay et al.
FREE RADICAL BIOLOGY AND MEDICINE (2011)
Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2
Yvette Drew et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer.
Joyce O'Shaughnessy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Loss of poly(ADP-ribose) polymerase 1 attenuates renal fibrosis and inflammation during unilateral ureteral obstruction
Jinu Kim et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2011)
Oocyte Numbers in the Mouse Increase after Treatment with 5-Aminoisoquinolinone: A Potent Inhibitor of Poly(ADP-ribosyl)ation
Hong Qian et al.
BIOLOGY OF REPRODUCTION (2010)
Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin
Kedar Hastak et al.
CANCER RESEARCH (2010)
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Peter C. Fong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
Evaluation of 5-aminoisoquinoline (5-AIQ), a novel PARP-1 inhibitor for genotoxicity potential in vitro and in vivo
K. R. Vinod et al.
TOXICOLOGY MECHANISMS AND METHODS (2010)
The Effect of Antioxidant on Development of Fibrosis by Cisplatin in Rats
Yoshiko Kawai et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2009)
PARP-1 Inhibits Glycolysis in Ischemic Kidneys
Kishor Devalaraja-Narashimha et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
N. Pabla et al.
KIDNEY INTERNATIONAL (2008)
Cisplatin nephrotoxicity: A review
Xin Yao et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2007)
Magnesium depletion enhances cisplatin-induced nephrotoxicity
H Lajer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Cisplatin: mode of cytotoxic action and molecular basis of resistance
ZH Siddik
ONCOGENE (2003)
Urinary N-acetyl-β-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis
C Bazzi et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2002)
分享论文
